From: Impact of oncologist payment method on health care outcomes, costs, quality: a rapid review
MEDLINE | ||
1 payment by results.mp. | 132 | |
2 activity based funding.mp. | 34 | |
3 prospective payment.mp. | 2471 | |
4 results based purchasing.mp. | 0 | |
5 pay for performance.mp. | 1388 | |
6 value based purchasing.mp. | 406 | |
7 performance based payment.mp. | 32 | |
8 Value-Based Purchasing/ | 221 | |
9 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 | 4376 | |
10 (salar* or cash or funding or remunerat* or reimburs* or capitation).m_titl. | 10,331 | |
11 exp reimbursement mechanisms/or exp fee-for-service plans/or exp prospective payment system/ | 19,943 | |
12 exp “Fees and Charges”/ | 14,265 | |
13 economics, medical/or fees, medical/or exp Economics, Dental/ | 4119 | |
14 exp Income/ | 30,587 | |
15 “costs and cost analysis”/ | 17,763 | |
16 exp models, economic/ | 9415 | |
17 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 | 91,620 | |
18 Physician Incentive Plans/ | 1686 | |
19 exp Physicians/ec [Economics] | 2901 | |
20 economics, medical/or fees, medical/ | 3308 | |
21 Physician’s Practice Patterns/ | 38,532 | |
22 “episode of care”/ | 1314 | |
23 Patient Care Bundles/ | 53 | |
24 (physician* adj3 (remunerat* or reimburs* or payment*)).mp. [mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier] | 1082 | |
25 exp reimbursement mechanisms/or exp fee-for-service plans/or exp prospective payment system/ | 19,943 | |
26 exp health personnel/ec | 8622 | |
27 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 | 70,140 | |
28 exp Neoplasms/ | 1,465,616 | |
29 medical oncology/or radiation oncology/ | 12,921 | |
30 exp Antineoplastic Agents/ | 503,154 | |
31 Cancer Care Facilities/ | 2772 | |
32 Oncology Nursing/or Oncology Service, Hospital/ | 6186 | |
33 (cancer* or oncolog* or chemotherap* or radiotherap* or radiation therap*).m_titl. | 549,429 | |
34 28 or 29 or 30 or 31 or 32 or 33 | 1,800,023 | |
35 17 and 27 and 34 | 983 | |
36 exp Canada/ | 77,345 | |
37 (canad* or british columbia or alberta or ontario or quebec or manitoba or saskatchewan or nova scotia or new brunswick or newfoundland or prince edward island).mp. [mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier] | 118,540 | |
38 36 or 37 | 118,680 | |
39 27 and 34 and 38 | 285 | |
40 9 and (10 or 11 or 12 or 13 or 14 or 15 or 16) and 27 and 34 | 47 | |
41 9 and 27 and 34 | 50 | |
42 9 and 34 | 99 | |
43 9 and 27 and 38 | 39 | |
44 9 and 34 and 38 | 4 | |
45 39 or 40 or 41 or 42 or 43 or 44 | 419 | |
46 limit 45 to yr = “2005 -Current” | 286 | |
47 limit 46 to english language | 275 | |
Embase | ||
Embase <1974 to 2015 May 14> | ||
# | Search statement | Results |
1 | payment by results.mp. | 253 |
2 | activity based funding.mp. | 58 |
3 | prospective payment.mp. | 8724 |
4 | results based purchasing.mp. | 0 |
5 | pay for performance.mp. | 1859 |
6 | value based purchasing.mp. | 320 |
7 | performance based payment.mp. | 43 |
8 | Value-Based Purchasing/ | 2810 |
9 | 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 | 13,742 |
10 | (salar* or cash or funding or remunerat* or reimburs* or capitation).m_titl. | 18,835 |
11 | exp reimbursement mechanisms/or exp fee-for-service plans/or exp prospective payment system/ | 55,981 |
12 | exp “Fees and Charges”/ | 35,171 |
13 | economics, medical/or fees, medical/or exp Economics, Dental/ | 651,978 |
14 | exp Income/ | 71,061 |
15 | “costs and cost analysis”/ | 53,721 |
16 | exp models, economic/ | 115,183 |
17 | 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 | 857,409 |
18 | Physician Incentive Plans/ | 51,522 |
19 | exp Physicians/ec [Economics] | 0 |
20 | economics, medical/or fees, medical/ | 45,653 |
21 | Physician’s Practice Patterns/ | 183,699 |
22 | “episode of care”/ | 209,403 |
23 | Patient Care Bundles/ | 188 |
24 | (physician* adj3 (remunerat* or reimburs* or payment*)).mp. [mp = title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword] | 5896 |
25 | exp reimbursement mechanisms/or exp fee-for-service plans/or exp prospective payment system/ | 55,981 |
26 | exp health personnel/ec | 0 |
27 | 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 | 506,044 |
28 | exp Neoplasms/ | 3,504,879 |
29 | medical oncology/or radiation oncology/ | 108,563 |
30 | exp Antineoplastic Agents/ | 1,565,429 |
31 | Cancer Care Facilities/ | 19,458 |
32 | Oncology Nursing/or Oncology Service, Hospital/ | 25,476 |
33 | (cancer* or oncolog* or chemotherap* or radiotherap* or radiation therap*).m_titl. | 1,058,603 |
34 | 28 or 29 or 30 or 31 or 32 or 33 | 4,403,463 |
35 | 17 and 27 and 34 | 12,766 |
36 | exp Canada/ | 136,398 |
37 | (canad* or british columbia or alberta or ontario or quebec or manitoba or saskatchewan or nova scotia or new brunswick or newfoundland or prince edward island).mp. [mp = title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword] | 228,077 |
38 | 36 or 37 | 228,077 |
39 | 27 and 34 and 38 | 1648 |
40 | 9 and (10 or 11 or 12 or 13 or 14 or 15 or 16) and 27 and 34 | 367 |
41 | 9 and 27 and 34 | 382 |
42 | 9 and 34 | 554 |
43 | 9 and 27 and 38 | 118 |
44 | 9 and 34 and 38 | 14 |
45 | 39 or 40 or 41 or 42 or 43 or 44 | 2304 |
46 | limit 45 to yr = “2005 -Current” | 1833 |
47 | limit 46 to english language | 1788 |
48 | “health policy economics and management”.ec. | 504,366 |
49 | 47 and 48 | 416 |
50 | (physician* and (fee or fees or pay* or remunerat* or compensat* or purchas* or reimburs*)).m_titl. | 2372 |
51 | limit 50 to (english language and yr = “2005 -Current”) | 694 |
52 | 49 or 51 | 1104 |
53 | limit 52 to yr = “2013 -Current” | 291 |
54 | 47 and physician*.mp. and (fee or fees or pay* or remunerat* or compensat* or purchas* or reimburs*).mp. [mp = title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword] | 151 |
55 | 52 or 54 | 1177 |
56 | limit 55 to exclude medline journals | 85 |
57 | 53 or 56 | 352 |
58 | remove duplicates from 57 | 342 |
EBM Reviews | ||
EBM Reviews - Cochrane Database of Systematic Reviews <2005 to December 2014> | ||
# | Search statement | Results |
1 | (Cochrane Effective Practice and Organisation of Care Group).mp. [mp = title, short title, abstract, full text, keywords, caption text] | 91 |
2 | 1 and (canad* or british columbia).ti, kw. | 0 |
3 | 1 and (cancer* or oncolog* or neoplasms or tumor* or tumour* or chronic).ti,kw. | 3 |
4 | 1 and (physician* or specialit* or specialt* or dentist* or cost* or financ* or econom* or fees or reimburs* or pay* or salar* or remunerat* or fund* or cash or incentive*or bundle* or performance or capitation or pattern* or episode*).ti, kw. | 25 |
5 | remunerat*.ti, kw. | 1 |
6 | 3 or 4 or 5 | 28 |